Dr. Robert D. Mass M.D. serves as Chief Medical Officer of the Company. Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company’s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio. Previously he served as clinical science leader for Herceptin® from 1999 to 2002, Tarceva® from 2002 to 2003, and Avastin®, currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass earned his bachelor’s degree in Economics from Tufts University and his medical degree from Oregon Health & Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
As the Chief Medical Officer of MEI Pharma Inc, the total compensation of Robert Mass at MEI Pharma Inc is 674,275$. There are 5 executives at MEI Pharma Inc getting paid more, with Daniel Gold having the highest compensation of 1,854,410$.
Robert Mass is 65, he's been the Chief Medical Officer of MEI Pharma Inc since 2011. There are 5 older and 9 younger executives at MEI Pharma Inc. The oldest executive at MEI Pharma Inc is Kevan Clemens, 75, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Over the last 12 years, insiders at MEI Pharma Inc have traded over 26,282,680$ worth of MEI Pharma Inc stock and bought 597,450 units worth 2,541,200$ . The most active insiders traders include Ventures Vii, Llc Vivo Vent...、Leaf Ventures Ii, L.P.New L...、Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of 360,383$. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth 329,211$.
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
MEI Pharma Inc executives and other stock owners filed with the SEC include: